IP Library Granted Patent US 8,652,467
Granted Patent B2
US 8,652,467 · App. 12/090,164 · Granted Feb 18, 2014

Dek protein compositions and methods of using the same

Inventors: David M. Markovitz (Ann Arbor, MI); Nirit Mor-Vaknin (Ann Arbor, MI); Michael Khodadoust (Ann Arbor, MI); Barbara S. Adams (Ann Arbor, MI)
Assignee: The Regents of the University of Michigan
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,652,467
App. No.
12/090,164
Granted
Feb 18, 2014
Kind
B2
Abstract

The present invention relates to DEK protein compositions (e.g., antibodies, small molecule inhibitors, siRNAs) and methods of using the same. In particular, the present invention provides compositions and methods for treating autoimmune disease (e.g., juvenile rheumatoid arthritis, lupus, etc.) and for inhibiting inflammation (e.g., associated with autoimmune disease) and cellular chemotaxis (e.g., of neutrophils, NK cells and T cells). The present invention further provides a diagnostic marker (e.g., DEK antigen) for autoimmune disease.

Claims (9)

1. A method of treatment for rheumatoid arthritis comprising administering to a subject having rheumatoid arthritis a composition comprising a DEK inhibitor under conditions such that the expression of DEK is reduced in said subject wherein said DEK inhibitor is an anti-DEK antibody.

2. The method of claim 1 , wherein said anti-DEK antibody is a monoclonal antibody.

3. The method of claim 1 , wherein said anti-DEK antibody is a polyclonal antibody.

4. The method of claim 1 , wherein said rheumatoid arthritis is juvenile rheumatoid arthritis (JRA).

5. The method of claim 1 , wherein the antibody inhibits chemotaxis of cells in the subject.

6. The method of claim 5 , wherein said anti-DEK antibody is a monoclonal antibody.

7. The method of claim 5 , wherein said anti-DEK antibody is a polyclonal antibody.

8. The method of claim 5 , wherein said antibody reduces activity and/or function of DEK.

9. The method of claim 8 , wherein said antibody inhibits chemotaxis of neutrophils, CD8+ T cells, and NK cells.

Assignments (3)
CONFIRMATORY LICENSE Recorded Apr 16, 2012
From: UNIVERSITY OF MICHIGAN
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 028050/0419 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 8, 2008
From: MARKOVITZ, DAVID M.; MOR-VAKNIN, NIRIT; KHODADOUST, MICHAEL; ADAMS, BARBARA S.
To: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Reel/Frame 021495/0005 →
CONFIRMATORY LICENSE Recorded May 1, 2008
From: UNIVERSITY OF MICHIGAN
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 020887/0374 →
Continuity (2)
Provisional Application 60726674 · Oct 14, 2005
Related Publication 20090004197A1 · Jan 1, 2009